Any current/future new fundraising through debt or equity?

No additional one-off costs or significant new fundraising through debt or equity anticipated at this point. All M&A-related costs have already been spent. Ongoing costs are primarily related to post-merger integration consultancy fees, which are not substantial. No explicit mention of planned new debt or equity fundraising in the call transcript. Focus remains on operational integration and efficiency improvements post Cenexi acquisition rather than new fundraising.

Any current/future capex/capital investment/strategic investment?

Total capex incurred in Q1 FY'24 was INR 687 million, primarily on Suite 9 Combi-line. Adding new capabilities such as Microsphere Combi-line and additional Bag line at Pashamylaram facility, Hyderabad. Post-acquisition of Cenexi, assessing Cenexi's future cash requirements for capex geared towards operational improvements and asset creation for growth. Dedicated cross-functional team working on Cenexi integration to optimize operations and realize synergies. Investment focus on new technologies like oncology pre-filled syringe, colored products, and sterile gels from Cenexi’s portfolio. No si

Future growth expectations in sales/revenue/volumes?

U.S. Market: Steady sequential growth expected quarter-on-quarter with new launches driving about 20% growth in U.S. from new products and volumes; continued ramp-up of Enoxaparin volumes expected from next quarter after inventory rationalization. New Product Launches: 23 molecules launched in Q1 in U.S. with further 12-13 product launches planned next quarter; target around 40 product launches per year going forward. Base Business Growth: 4% year-on-year growth in base business revenue excluding acquisitions. Rest of World (ROW): Gradual business growth anticipated, with focus shifting

Future growth expectations in earnings/operating earnings/profits/EPS?

Base business grew 4% YoY in Q1FY'24; expected steady sequential growth in US market driven by new product launches and volume growth. Enoxaparin sales in US had inventory rationalization in Q1 but expected to pick up from next quarter. Launch target: Around 40 products annually in the US market including tech transfers. Shift from low-margin products (e.g., Heparin, Enoxaparin in ROW) toward higher-margin businesses like Cenexi CDMO operations with high gross margins (~76%). EBITDA margin (ex-Cenexi) maintained at healthy 30%; PAT margin at 21% in base business. Gross margin improve

Current/ Expected Orderbook/ Pending Orders?

The transcript does not provide specific quantitative details on the current or expected order book or pending orders for Gland Pharma as of Q1 FY24. However, management highlights: - A positive start to FY24 with revenue growth and strong operational performance. - Multiple product launches in the U.S., including 23 products launched in Q1 and plans for about 40 annual launches. - New launches and relaunches are driving volume growth, especially in the U.S. market. - The company is rebuilding business volumes with customers following recent contract shifts. - Several technology tran

Gland Pharma LtdQ1 FY24Pharmaceuticals & Biotechnology

Gland Pharma Ltd Q1 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹3,019.8P/E: 43.5Market Cap: ₹49.8K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

U.S. Market: Steady sequential growth expected quarter-on-quarter with new launches driving about 20% growth in U.S. from new products and volumes; continued ramp-up of Enoxaparin volumes expected from next quarter after inventory rationalization.
New Product Launches: 23 molecules launched in Q1 in U.S. with further 12-13 product launches planned next quarter; target around 40 product launches per year going forward.
Base Business Growth: 4% year-on-year growth in base business revenue excluding acquisitions.
Rest of World (ROW): Gradual business growth anticipated, with focus shifting to higher margin products and Cenexi portfolio, which showed 62% YoY revenue growth.
India Market: 27% revenue growth in Q1 FY24.
Cost Efficiency: Opportunities exist to improve operational efficiencies, reduce costs, and increase profitability.
Oncology Products: Demand expected to remain high due to ongoing shortages, supporting growth in onco injectables segment.

Margin guidance

Category 3

Base business grew 4% YoY in Q1FY'24; expected steady sequential growth in US market driven by new product launches and volume growth.
Enoxaparin sales in US had inventory rationalization in Q1 but expected to pick up from next quarter.
Launch target: Around 40 products annually in the US market including tech transfers.
Shift from low-margin products (e.g., Heparin, Enoxaparin in ROW) toward higher-margin businesses like Cenexi CDMO operations with high gross margins (~76%).
EBITDA margin (ex-Cenexi) maintained at healthy 30%; PAT margin at 21% in base business.
Gross margin improvement and operational efficiencies expected from synergies with Cenexi including new technologies and cost reduction.
Profit share expected to remain around 8-11%.
Capex expected for Cenexi post-acquisition to drive operational improvements and future growth.
Overall, management anticipates growth fueled by new launches, higher-margin portfolio, and integration synergies for improved earnings and profitability.

See what Gland Pharma Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

No additional one-off costs or significant new fundraising through debt or equity anticipated at this point.
All M&A-related costs have already been spent.
Ongoing costs are primarily related to post-merger integration consultancy fees, which are not substantial.
No explicit mention of planned new debt or equity fundraising in the call transcript.
Focus remains on operational integration and efficiency improvements post Cenexi acquisition rather than new fundraising.

Order book

The transcript does not provide specific quantitative details on the current or expected order book or pending orders for Gland Pharma as of Q1 FY24.
However, management highlights:
- A positive start to FY24 with revenue growth and strong operational performance.
- Multiple product launches in the U.S., including 23 products launched in Q1 and plans for about 40 annual launches.
- New launches and relaunches are driving volume growth, especially in the U.S. market.
- The company is rebuilding business volumes with customers following recent contract shifts.
- Several technology transfer projects and partnerships are underway to expand the high-margin product portfolio.
While no explicit order backlog data is disclosed, the focus on multiple launches and ongoing supply contracts indicates a robust opportunity pipeline.

See what Gland Pharma Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Total capex incurred in Q1 FY'24 was INR 687 million, primarily on Suite 9 Combi-line.
Adding new capabilities such as Microsphere Combi-line and additional Bag line at Pashamylaram facility, Hyderabad.
Post-acquisition of Cenexi, assessing Cenexi's future cash requirements for capex geared towards operational improvements and asset creation for growth.
Dedicated cross-functional team working on Cenexi integration to optimize operations and realize synergies.
Investment focus on new technologies like oncology pre-filled syringe, colored products, and sterile gels from Cenexi’s portfolio.
No significant one-time costs expected related to M&A; only minor consultancy fees anticipated for post-merger integration.
Overall, capital investments are targeted to enhance operational efficiency, capacity expansion, and integration benefits over 1-2 years.

Track Gland Pharma Ltd — get its next earnings analysis in your feed

How does Gland Pharma Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisGland Pharma Ltd

Rev 3Mar 3

See where Gland Pharma Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Gland Pharma Ltd rank in Pharmaceuticals & Biotechnology?

Compare Gland Pharma Ltd against every Pharmaceuticals & Biotechnology company (Q1 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Gland Pharma Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Bajaj Healthcare (Q2 FY27)
Operating Margin: Operating Margin = (EBITDA / Revenue from operations) × 100 = (2,770.29 / 14,791.49) × 100 ≈ 18.73% . Key results statement takeaways from Baj
Himalaya Nutravedics (Q2 FY27)
Reported revenue from operations for FY26: ₹4,306.8 lakhs, a year-on-year increase of 105.1% from ₹2,099.7 lakhs in FY25 (Page 22, 14, 5, 4). Key investor prese
Granules India (Q2 FY27)
Granules plans to invest about ₹2,000 crore in organic capital expenditure over the next 3-4 years. Key concall takeaways from Granules India Ltd's Q2 FY27…
Bajaj Healthcare (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Gland Pharma Ltd Q1 FY24 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Gland Pharma Ltd rank in Pharmaceuticals & Biotechnology?

Continue your research

What Gland Pharma Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season